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Pneumocystis carinii Pneumonia Among Renal Transplant
Recipients Despite Antibiotic Prophylaxis
Sze-Kit Yuen, Ka-Fai Yim, Yuen-Fun Mak,1 Kwok-Hong Chu, Hon-Lok Tang,
 Ka-Shun Fung, Wai-Han Chan, Kwok-Lung Tong
Pneumocystis carinii pneumonia (PCP) is a well-known opportunistic infection in renal transplant recipients;
it is associated with high mortality, mostly within the first 6 months post-transplantation. The disease has been
effectively prevented by routine antibiotic prophylaxis. Recently, however, we encountered three consecutive
cases of PCP; one developed the disease at 8 months and another at 11 months post-transplantation. An overall
assessment of a patient’s degree of immunosuppression is essential when considering the duration of PCP
prophylaxis. Instead of the routine regimen of 6 months, 1-year PCP prophylaxis may be required for those
who are on both tacrolimus and mycophenolate mofetil. [Hong Kong J Nephrol 2005;7(2):93–6]
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INTRODUCTION
Pneumocystis carinii pneumonia (PCP) is a disease that
causes severe alveolar damage [1] and which has a high
mortality rate [2,3]. It is a well-recognized opportunis-
tic infection among renal transplant recipients [4];
approximately 5% of those not taking antibiotic
prophylaxis develop PCP [5]. It usually occurs 3–6
months after renal transplantation [6–9], although it can
appear as late as 9 years after [10].
Centers using the regimens of co-trimoxazole
(trimethoprim-sulfamethoxazole, TMP-SMX) pro-
phylaxis for the initial 4 months [11] or 6 months [8]
reported no subsequent PCP cases. Indeed, it should
now be standard practice to prescribe PCP prophylaxis
in all renal transplant recipients, with co-trimoxazole
being the drug of choice [4]. Our center implemented
routine PCP prophylaxis for all renal transplant
recipients in 1993. The majority of our patients receive
oral co-trimoxazole (TMP-SMX 80 mg/400 mg) for
6 months. Only isolated cases of PCP have been
diagnosed since 1993, notably in transplant recipients
who are either noncompliant or contraindicated to co-
trimoxazole prophylaxis. Over a period of 3 months,
however, we encountered three cases of PCP. Of note,
two of these patients developed PCP more than 8
months post-transplantation, when they had already
been taken off their PCP prophylaxis.
CASE REPORTS
Case 1
A 49-year-old man with a past history of IgA
nephropathy was diagnosed with end-stage renal failure
requiring hemodialysis in 1997. In November 2004, he
underwent cadaveric renal transplantation in Mainland
China. Induction immunosuppressives included ster-
oid, tacrolimus, mycophenolate mofetil (MMF) and
daclizumab. Postoperatively, he had been treated with
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pulse doses of steroids for presumed acute rejection
without histologic proof. His renal function was normal
when he returned to Hong Kong. We started him on
oral co-trimoxazole 480 mg daily as PCP prophylaxis,
but he did not take it regularly.
He presented on 27th February 2005 (approximately
3 months post-renal transplantation) with a 1-week
history of low-grade fever and shortness of breath. At
that time, his immunosuppressives included pred-
nisolone 10 mg om, tacrolimus 1 mg om and 0.5 mg
pm, and MMF 500 mg bd. He was also on diltiazem 30
mg tds, and his latest tacrolimus trough level was
9.9 μg/L.
Chest X-ray on admission showed bilateral lower
zone infiltrates. MMF was stopped and he was
empirically started on intravenous co-trimoxazole,
ganciclovir and piperacillin/tazobactam. Transbronchial
biopsy and bronchoalveolar lavage the next day
confirmed PCP. High-dose intravenous steroid was
added. He ran a stormy course requiring prolonged
mechanical ventilation (Figure). Tacrolimus was
stopped. His clinical course was further complicated
by noninvasive pulmonary aspergillosis, asymptomatic
cytomegalovirus pp65 antigenemia, ganciclovir-related
bone marrow suppression and pseudomonas pneu-
monia; all were finally overcome. He was discharged
7 weeks after admission with fair exercise tolerance
and normal renal function.
Case 2
A 60-year-old man with a past history of hypertension,
polycystic kidney disease and chronic renal failure
underwent pre-emptive cadaveric renal transplantation
in Mainland China in August 2004. No antibody was
used at induction. He completed a 6-month course of
oral co-trimoxazole 480 mg as PCP prophylaxis. He
did not experience any rejection or infective episode,
and he had normal renal function.
On 2nd May 2005 (approximately 8 months post-
transplantation), he was hospitalized for cough,
productive sputum and low-grade fever. His
immunosuppressives included prednisolone 7.5 mg
daily, tacrolimus 3 mg om and 2.5 mg pm, and MMF
500 mg bd. His latest tacrolimus trough level was
10.1 μg/L.
His white cell count was 5.9 × 109/L with relative
neutrocytosis (82.2%). Chest X-ray showed left lower
zone haziness. MMF was stopped and intravenous
amoxicillin-clavulanate and oral clarithromycin started.
His fever subsided and he remained clinically stable
for the next 5 days. His sputum culture yielded
Flavobacterium spp. Antibiotics were switched to
levofloxacin according to sensitivity.
Over the next 3 days, he became febrile again and
required up to 6 L/min oxygen. Chest X-ray confirmed
progression of lower zone consolidation. Intravenous
piperacillin/tazobactam and co-trimoxazole were
added. Bronchoalveolar lavage and transbronchial lung
biopsy confirmed PCP. He required noninvasive
positive pressure ventilation (NIPPV) temporarily, and
was discharged 5 weeks after hospitalization with
normal renal function and exercise tolerance.
Case 3
A 52-year-old man with a history of end-stage renal
failure due to hypertensive nephropathy underwent
cadaveric renal transplantation in June 2004 in
Mainland China. No antibody induction was used. He
suffered one episode of Banff class IA acute cellular
rejection in August 2004, which was partially reversed
by pulse methylprednisolone. Creatinine level stabilized
at around 200 μmol/L thereafter. He completed a
standard 6-month course of co-trimoxazole PCP
prophylaxis.
He presented on 9th May 2005 (approximately 11
months post-transplantation) for cough and fever. His
immunosuppressives included prednisolone 10 mg om,
tacrolimus 4 mg bd, and MMF 750 mg bd. His latest
tacrolimus trough level was 7.8 μg/L.
He was started on levofloxacin for right lower lobe
pneumonia, which was confirmed by chest X-ray. MMF
was stopped. He discharged himself against medical
advice the next day but continued to take oral
levofloxacin. He presented with shortness of breath 3
days later, and chest X-ray showed progression of
Figure. Case 1: chest X-ray on day 12 of hospitalization shows
bilateral diffuse lung field haziness due to Pneumocystis carinii
pneumonia.
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consolidation to the right lower lobe as well. Antibio-
tics were changed to piperacillin/tazobactam and
azithromycin. Despite this, he deteriorated rapidly and
required mechanical ventilation. Bronchoalveolar
lavage confirmed the diagnosis of PCP. Tacrolimus was
stopped and intravenous co-trimoxazole and steroids
started. His clinical course was complicated by uni-
lateral pneumothorax, acute renal failure, recurrent line
sepsis and fungemia. He died 8 weeks after hospi-
talization.
DISCUSSION
Case clustering and possible nosocomial transmission
of Pneumocystis carinii has been reported in renal
transplant recipients in their early post-transplantation
period [12]. It is unusual to encounter three cases of
PCP within such a short period of time (3 months), but
apparently, our three patients did not have direct contact
with one another prior to symptom onset. Genotyping
of the organism was not performed, so a definite epi-
demiologic link could not be established. Nevertheless,
exposure to a common hospital environment reservoir
cannot be ruled out.
PCP prophylaxis failures may be due to non-
compliance to chemoprophylaxis and recent intensi-
fied immunosuppression [12]. Case 1 had similar rea-
sons for failure. Other reasons for prophylaxis failure
[13] include sulfonamide resistance related to mutation
of dihydropterate synthase [14].
Cases 2 and 3 are special in that they developed
PCP during the late transplantation period (i.e. > 8
months post-transplantation), when they were on
relatively low-dose immunosuppression and PCP
prophylaxis had stopped. To our knowledge, late PCP
in renal transplant recipients has not been reported in
Hong Kong. It is interesting to note that all of these
three patients were on both tacrolimus and MMF. Their
high immunosuppressive potential [9,15] probably
explains the higher risks of infectious complications.
The duration of co-trimoxazole prophylaxis given
by different renal transplant centers varies from a few
months to more than 12 months [16,17]. The recognized
cross-resistance between components of co-trimoxazole
and sulfadoxine/pyrimethamine means that its
prolonged use promotes selection of drug-resistant
Plasmodium falciparum [18,19] and emergence of
resistant bacteria [14]. Therefore, although PCP has a
mortality rate of up to 37% [2], adopting a practice of
routine lifelong prophylaxis [20] is probably unwise.
When considering the duration of PCP prophylaxis,
transplant centers should adopt an individualized
approach. We believe the overall degree of immuno-
suppression [21], rather than any single immuno-
suppressive agent, to be predictive of the risk of PCP
development. Those who have been given high-dose
pulse steroids, T cell depleting antibody, potent
immunosuppressive regimen (i.e. concomitant use of
tacrolimus and MMF) and who are elderly [22] are
particularly at risk; a prolongation of PCP prophylaxis
up to 1 year is probably warranted in these individuals.
In conclusion, we reported three consecutive cases
of PCP within a 3-month period in our renal unit. Late
presentation of PCP is possible in this era of heavy
immunosuppression. An individualized approach
should be adopted when deciding the duration of PCP
prophylaxis. Oral co-trimoxazole for 1 year is probably
appropriate for those taking both tacrolimus and MMF.
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